Plasma microrna expression profile for reduced ejection fraction in dilated cardiomyopathy

Abstract

The left ventricular (LV) ejection fraction (EF) is key to prognosis in dilated cardiomyopathy (DCM). Circulating microRNAs have emerged as reliable biomarkers for heart diseases, included DCM. Clinicians need improved tools for greater clarification of DCM EF categorization, to identify high-risk patients. Thus, we investigated whether microRNA profiles can categorize DCM patients based on their EF. 179-differentially expressed circulating microRNAs were screened in two groups: (1) non-idiopathic DCM; (2) idiopathic DCM. Then, 26 microRNAs were identified and validated in the plasma of ischemic-DCM (n = 60), idiopathic-DCM (n = 55) and healthy individuals (n = 44). We identified fourteen microRNAs associated with echocardiographic variables that differentiated idiopathic DCM according to the EF degree. A predictive model of a three-microRNA (miR-130b-3p, miR-150-5p and miR-210-3p) combined with clinical variables (left bundle branch block, left ventricle end-systolic dimension, lower systolic blood pressure and smoking habit) was obtained for idiopathic DCM with a severely reduced-EF. The receiver operating characteristic curve analysis supported the discriminative potential of the diagnosis. Bioinformatics analysis revealed that miR-150-5p and miR-210-3p target genes might interact with each other with a high connectivity degree. In conclusion, our results revealed a three-microRNA signature combined with clinical variables that highly discriminate idiopathic DCM categorization. This is a potential novel prognostic biomarker with high clinical value.

MicroRNAs in Hypertrophic, Arrhythmogenic and Dilated Cardiomyopathy

“…A recent study conducted by Calderon-Dominguez in 2021 presented a predictive three-miRNAs model (high levels of miR-130b-3p, miR-150-5p, and miR-210-3p) that, combined with clinical variables, could distinguish idiopathic DCM with severe reduced systolic ejection fraction from patients with moderately reduced ejection fraction [77].…”

Robust Rank Aggregation and Least Absolute Shrinkage and Selection Operator Analysis of Novel Gene Signatures in Dilated Cardiomyopathy

“…The criteria for selecting these datasets included: (1) Gene expression data must be available for both DCM and NCT samples, (2) at least 5,000 genes must be included when the microarray platform is used for expression profiling. In general, DCM is defined by patients with clinical features of a left ventricular end-diastolic diameter over than 56 mm and a left ventricular ejection fraction (LVEF) <50% ( 14 ). Exclusion criteria were genetic DCM or any cardiovascular, life-limiting systemic condition or an infectious or tumoral condition that may influence the definition of DCM.…”

A Systematic Review of miRNA and cfDNA as Potential Biomarkers for Liquid Biopsy in Myocarditis and Inflammatory Dilated Cardiomyopathy

“…This model allowed them to increase the AUC for distinguishing severe DCM from moderate DCM from 0.78 (for the best miRNA—miR-145) to 0.96. However, the miRNA yielding the highest AUC on its own was not identified as a prediction factor in this model [ 43 ].…”